PhOx430 Clinical Trials

1 actively recruiting trial

Also known as: Dose Escalation Phase - STEP 1 and STEP 2, Dose Escalation Phase - STEP 3 (Dosing-optimization Cohort)

Pipeline

Phase 1: 1

Top Sponsors

Phost'In Therapeutics1

Indications

Malignant Tumor1
Metastatic Cancer1
Glioblastoma Multiforme1
Advanced Solid Tumor1
Cancer1

Other1 trial

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.